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Hypertriglyceridemia is associated with in-
creases in atherosclerotic cardiovascular disease 
(ASCVD) risk and remains prevalent among  adults 
in the United States (US) due to an increasing 
prevalence of obesity, insulin resistance, diabetes 
mellitus, and other risk factors. Guidelines suggest 
target triglycerides (TG) should be < 150 mg/dL 
[1]. However, a number of studies have suggested 
that reduced cardiovascular risk is associated with 
lower TG [2–4]. Indeed, ASCVD risk remains even 
in patients with moderately elevated TG despite 
the control of low-density lipoprotein cholesterol 
(LDL-C) with statin therapy [2, 4–6]. The recently 
completed REDUCE-IT trial investigated the ef-
fects of icosapent ethyl 4 g/day in statin-treated 
patients with established cardiovascular disease, 
diabetes and other risk factors and TG 135–499 
mg/dL. REDUCE-IT found a significant reduc-
tion in major adverse cardiovascular events when 
compared with a placebo (hazard ratio [HR] 0.75; 
95% confidence interval [CI] 0.68–0.83; p < 0.001) 
over a median follow-up time of 4.9 years [4]. 
Subgroup analyses showed similar risk reduction 
both in persons with or without baseline TG ≥ 150 
mg/dL [4]. Based on the findings of REDUCE-IT, 
the American Diabetes Association Standards of 
Care now includes a Level A recommendation 
that icosapent ethyl be considered for reducing 
cardiovascular risk in statin-treated patients with 
controlled LDL-C, elevated TG (135–499 mg/dL), 
diabetes, ASCVD or other cardiac risk factors [7]. 
The objective of this analysis was to examine 
the prevalence of TG ≥ 135 mg/dL in the overall US 
adult population and in those treated with statins, 
in accordance with the presence of ASCVD and/ 
/or diabetes. 
This analysis included laboratory data, medical 
history, and prescription data from subjects aged 
20 years and older who participated in the US Na-
tional Health and Nutrition Examination Survey 
(NHANES; 2007–2014) and had morning fasting 
TG available. For the current report, the propor-
tion and number (weighted in millions to the US 
population) of individuals with TG ≥ 135 mg/dL 
was estimated according to the following factors: 
statin use, LDL-C < 100 mg/dL, diabetes, ASCVD, 
and/or age ≥ 45 years, as well as the proportion and 
number of individuals with multiple risk factors. All 
analyses used the NHANES 8-year sample weight-
ing to project the US population in millions. The 
general methodology of NHANES data collection 
was published previously [8].
Diabetes was defined as fasting glucose 
≥ 126 mg/dL, non-fasting glucose ≥ 200 mg/dL, 
taking insulin or other medications to lower blood 
sugar, or diagnosed by a healthcare provider. LDL-C 
was calculated by the Friedewald equation.
The study sample included 40,617 individuals 
in the NHANES 2007–2014 survey. A total of 9593 
subjects, projected to represent 219.9 million US 
adults, met the entry criteria and were included 
in the analysis. As shown in Table 1, the overall 
proportion of US adults with TG ≥ 135 mg/dL was 
32.1% (representing 70.5 million individuals). 
Among statin-treated adults, the proportion with 
TG ≥ 135 mg/dL was 39.0% (15.2 million) and 
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ranged from 35.0% to 47.6% for those who also 
had LDL-C controlled to < 100 mg/dL, diabetes, 
and/or ASCVD (Table 1).
Based on the present analysis, more than 
30% of all adults in the US (70.5 million) have TG 
≥ 135 mg/dL, including 39.0% (15.2 million) of those 
being treated with statins. In a recent study of this 
population, 56.9 million US adults were estimated 
to have TG ≥ 150 mg/dL [9], resulting in 13.6 mil-
lion having TG ≥ 135 mg/dL and < 150 mg/dL based 
on that study and the present analysis.
Schwartz et al. [2] demonstrated a significant 
trend toward increased risk of both short- and 
long-term ASCVD following acute coronary syn-
drome, according to progressively higher tertiles 
or quintiles of TG concentrations (p = 0.03 and 
p < 0.001, respectively) [2]. They further reported 
that the adjusted risk of ASCVD increased by 1.8% 
for every 10 mg/dL increase in TG above 80 mg/dL. 
Another study reported a significantly elevated 
risk of myocardial infarction in patients with TG 
from 89 to 176 mg/dL, compared to those with TG 
< 89 mg/dL (HR 1.6; 95% CI 1.4–1.9), indicating 
substantially increased risk at higher TG levels 
[3]. In the placebo arm of REDUCE-IT, a primary 
composite endpoint event occurred in 22% of pa-
tients overall, and in 21% of the subset of patients 
with TG < 150 mg/dL, indicating substantial risk 
in such patients. 
The current report estimates that 4.8 million 
US adults on statin therapy with either ASCVD 
or diabetes have TG ≥ 135 mg/dL but LDL-C 
< 100 mg/dL and may be possible candidates 
for icosapent ethyl therapy for the reduction of 
ASCVD risk based on results from REDUCE-IT. 
Better efforts are needed to identify and address 
remaining residual ASCVD risk in statin-treated 
individuals with TG ≥ 135 mg/dL, including lifestyle 
modification adherence measures and the use of 
evidence-based pharmacologic therapies shown 
to reduce ASCVD risk.
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